Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;7(5):e35981.
doi: 10.1371/journal.pone.0035981. Epub 2012 May 29.

Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent

Affiliations

Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent

Sylvia Feyler et al. PLoS One. 2012.

Abstract

Regulatory T-cells (T(Reg) cells) are increased in patients with multiple myeloma (MM). We investigated whether MM cells could generate and/or expand T(Reg) cells as a method of immuno-surveillance avoidance. In an in vitro model, CD4(+)CD25(-)FoxP3(-) T-cells co-cultured with malignant plasma cells (primary MM cells and cell lines) induced a significant generation of CD4(+)CD25(+)FoxP3(+) inducible T(Reg) cells (tT(Reg) cells; p<0.0001), in a contact-dependent manner. tT(Reg) cells were polyclonal, demonstrated a suppressive phenotype and phenotypically, demonstrated increased FoxP3 (p = 0.0001), increased GITR (p<0.0001), increased PD1 (p = 0.003) and decreased CD62L (p = 0.007) expression compared with naturally occurring T(Reg) cells. FACS-sorted tT(Reg) cells differentiated into FoxP(+)IL-17(+) and FoxP3(-)IL-17(+) CD4(+) cells upon TCR-mediated stimulation. Blocking experiments with anti-ICOS-L MoAb resulted in a significant inhibition of tT(Reg) cell generation whereas both IL-10 & TGFβ blockade did not. MM tumour cells can directly generate functional T(Reg) cells in a contact-dependent manner, mediated by ICOS/ICOS-L. These features suggest that tumour generation of T(Reg) cells may contribute to evasion of immune surveillance by the host.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Regulatory T-cell induction by Myeloma tumour cells.
A. The expansion of FoxP3 +CD25+CD4+ natural TReg cells, expressed as a percentage of CD4+T-cells. TReg cells were enumerated in the PB of healthy donors, after 7 days in CM and 7 days co-cultured with mitomycin C-treated U266B cells (n = 4). Results represent all experiments, expressed as mean ± SEM and analyzed using a 1-way ANOVA and student t-test. B. Expansion of nTReg cells when co-culture with HMCL results from cell division, illustrated by a representative flow cytometry plot of CFSE dilution. C. The generation of FoxP3 +CD25+CD4+ T-cells, expressed as a percentage of CD4+T-cells, in a co-culture assay with mitomycin C-treated U266B cells (n = 6) with varying starting populations: PB MNC, PBL CD25 depleted and CD4+CD25- T-cells. Results demonstrate that increased generation of tumour-induced regulatory T-cells (tTReg cells) is seen with increasing purity of the seeded population. Results represent all experiments, expressed as mean ± SEM and analyzed using a 1-way ANOVA and student t-test. D. Representative flow cytometry plots demonstrating the generation of FoxP3 +CD25+CD4+ T-cells from CD4+CD25- T-cells through cell division of de novo generated FoxP3 + T-cells in a 7 day co-culture assay with mitomycin C-treated U266B cells. E. The generation of FoxP3 +CD25+CD4+ T-cells, expressed as a percentage of CD4+T-cells, in a co-culture assay of CD4+CD25 T-cells (n = 10) with mitomycin C-treated MM cell lines (U266B, JJN3, JIM3 & KMS11), an erythro-leukaemia cell line (K562) and non-heamatopoietic cell lines (Mel888 & HeLa). Results represent all experiments, expressed as mean ± SEM and analyzed using a 1-way ANOVA and student t-test (**p<0.001, *p<0.01). F. The generation of FoxP3 +CD25+CD4+ T-cells, expressed as a percentage of CD4+T-cells, in a co-culture assay with fresh BM-derived myeloma plasma cells from patient samples (n = 7). Results demonstrate that increased generation of tumour-induced regulatory T-cells (tTReg cells) is seen with primary myeloma cells. Results represent all experiments, expressed as mean ± SEM and analyzed using a 1-way ANOVA and student t-test.
Figure 2
Figure 2. Phenotypic characteristics of tumour-induced regulatory T-cells.
A. FoxP3 expression, as determined by mean fluorescence intensity (MFI) in natural TReg cells from healthy controls (Control PB, n = 43), PB from patients with MM (MM PB, n = 43) and tTReg cells (n = 15) generated in co-culture from CD4+CD25- T-cells (Kruskal-Wallis test). Results represent all experiments, expressed as mean ± SEM and analyzed using a 1-way ANOVA and student t-test. B. Representative histograms of naturally occurring TReg cell and tTReg cell surface expression of CD127, PD-1, GITR and CD62L. C. Summary of surface expression profiling of natural TReg cells and tTReg cells generated in co-culture, gated on FoxP3 +CD25+CD4+ T-cells (n = 4), expressed as mean fluorescence intensity (MFI). Results represent all experiments, expressed as mean ± SEM and analyzed using student t-test (*p<0.003, **p<0.0001).
Figure 3
Figure 3. Functional characteristics of tumour-induced regulatory T-cells.
A. Suppression of anti-CD3/anti-CD28-induced autologous T-cell proliferation by tumour-generated and naturally occurring TReg cells (n = 3), as determined by tritiated thymine incorporation. Results expressed as counts per minute (cpm)± SEM representing assays performed in triplicate. Key: Unstim – resting CD4+CD25- T cells, Stim – CD3/CD28 stimulated CD4+CD25- T-cells, 4∶1 etc – ratio of stimulated autologous T-cells to TReg cells. B. The generation of IL-10 in co-cultures of CD25-CD4+ sorted T-cells and HMCL, compared with HMCl alone and culture medium (n = 6, p = 0.0004). Results represent all experiments, expressed as mean±SEM and analyzed using student t-test. C. IL-10 production by tTReg cells after 7 days of co-cultures of CD25-CD4+ sorted T-cells and HMCL. Results represent all experiments, expressed as mean±SEM (n = 3) and analyzed using student t-test. D. IL-10 production by tTReg cells after 7 days of co-cultures of CD25-CD4+ sorted T-cells and HMCL. Results represent all experiments, expressed as mean±SEM (n = 3) and analyzed using student t-test. E. Representative flow cytometry plots demonstrating the generation of IFNγ+ FoxP3 +CD25+CD4+ T-cells from CD4+CD25- T-cells in a 7 day co-culture assay with mitomycin C-treated U266B cells. F. The proportion of IFNγ-producing FoxP3 +CD25+CD4+ T-cells detectable in the peripheral blood of age-matched controls (n = 15), patients with MM (n = 15) and tTReg cells generated in vitro after 7 days of co-cultures of CD25-CD4+ sorted T-cells and HMCL (n = 3). Histograms represent IFNγ production by cells gated on FoxP3/CD25/CD4 positive staing. Results expressed as mean±SEM.
Figure 4
Figure 4. Natural and tumour-induced regulatory T-cell plasticity.
A. The generation of IL-17 in co-culture supernatants of CD25-CD4+ sorted T-cells with HMCL, compared with HMCl alone and culture medium (n = 3). Results represent all experiments, expressed as mean±SEM. B. Representative dot-plots of IL-17 producing cells generated from re-stimulation of sorted tumour-generated and naturally occurring TReg cells after 5 days of re-stimulation. C. The proportion of IL-17 producing cells generated from re-stimulation of sorted tumour-generated and naturally occurring TReg cells, expressing FoxP3 after 5 days of re-stimulation, expressed as a percentage of CD4+ T-cells. Results expressed as mean±SEM.
Figure 5
Figure 5. In vitro mechanisms of tumour regulatory T-cell induction.
A. The generation of FoxP3 +CD25+CD4+ tTReg cells from CD4+CD25- T-cells, expressed as a percentage of CD4+T-cells, in a co-culture assay with mitomycin C-treated U266 cells with and without transwell inserts (n = 7). Results represent all experiments, represented as mean±SEM and analysed using a student t-Test. B. Surface expression of HLA-DR, ICOSL (CD275) and TGFβ by human myeloma cell lines. C. Inhibition of tTReg cells generation from CD4+CD25- T-cells by co-culture with HMCL (n = 3) through blockade of TGFβ and IL-10 using monoclonal antibodies and Latency-associated Peptide (LAP). Results represent all experiments, expressed as mean (±SEM). D. Surface expression of ICOS by TReg cells, presented as both percentage expression of CD4+CD25+ FoxP3 + cells and representative dot plots. Results represent all experiments, expressed as mean ±SEM (n = 3) and analysed using a student t-test. E. Inhibition of tTReg cells generation from CD4+CD25- T-cells by co-culture with HMCL through blockade of anti-ICOS-L (αICOS 1, 10, 100 µM) monoclonal antibody (n = 6), expressed as percentage of CD4+ T-cells and percent inhibition of tTReg cell generation. Results represent all experiments, illustrated as median with maximum and minimum values and analysed using a student t-test.

References

    1. Lizee G, Radvanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res. 2006;12:4794–4803. - PubMed
    1. Knutson KL, Disis ML, Salazar LG. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother. 2007;56:271–285. - PMC - PubMed
    1. Filaci G, Fenoglio D, Fravega M, Ansaldo G, Borgonovo G, et al. CD8+CD28 T Regulatory Lymphocytes Inhibiting T Cell Proliferative and Cytotoxic Functions Infiltrate Human Cancers. J Immunol. 2007;179:4323–4334. - PubMed
    1. Chen W, Jin W, Hardegen N, Lei KJ, Li L, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875–1886. - PMC - PubMed
    1. Cobbold SP, Graca L, Lin CY, Adams E, Waldmann H. Regulatory T cells in the induction and maintenance of peripheral transplantation tolerance. Transpl Int. 2003;16:66–75. - PubMed

Publication types

MeSH terms

Substances